Literature DB >> 8993098

Health state valuations from the general public using the visual analogue scale.

C Gudex1, P Dolan, P Kind, A Williams.   

Abstract

In the clinical and economic evaluation of health care, the value of benefit gained should be determined from a public perspective. The objective of this study was to establish relative valuations attached to different health states to form the basis for a 'social tariff' for use in quantifying patient benefit from health care. Three thousand three hundred and ninety-five interviews were conducted with a representative sample of the adult British population. Using the EuroQol health state classification and a visual analogue scale (VAS), each respondent valued 15 health states producing, in total, direct valuations for 45 states. Two hundred and twenty-one re-interviews were conducted approximately 10 weeks later. A near complete, and logically consistent, VAS data set was generated with good test-retest reliability (mean ICC = 0.78). Both social class and education had a significant effect, where higher median valuations were given by respondents in social classes III-V and by those with intermediate or no educational qualifications. These effects were particularly noticeable for more severe states. The use of such valuations in a social tariff raises important issues regarding the use of the VAS method itself to elicit valuations for hypothetical health states, the production of separate tariffs according to social class and/or education and the appropriate measure of central tendency.

Entities:  

Mesh:

Year:  1996        PMID: 8993098     DOI: 10.1007/bf00439226

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  31 in total

1.  The validity of a visual analogue scale in determining social utility weights for health states.

Authors:  E Nord
Journal:  Int J Health Plann Manage       Date:  1991 Jul-Sep

2.  EuroQol: health-related quality of life measurement. Valuations of health states by the general public in Norway.

Authors:  E Nord
Journal:  Health Policy       Date:  1991-06       Impact factor: 2.980

3.  Valuation of health states by the general public: feasibility of a standardized measurement procedure.

Authors:  M L Essink-Bot; G J Bonsel; P J van der Maas
Journal:  Soc Sci Med       Date:  1990       Impact factor: 4.634

4.  Quality of life: is it a practical tool in patients with vascular disease?

Authors:  W Humphreys; F Evans; T Williams
Journal:  J Cardiovasc Pharmacol       Date:  1994       Impact factor: 3.105

5.  Methods for measuring levels of well-being for a health status index.

Authors:  D L Patrick; J W Bush; M M Chen
Journal:  Health Serv Res       Date:  1973       Impact factor: 3.402

6.  Do patients' evaluations of a future health state change when they actually enter that state?

Authors:  H A Llewellyn-Thomas; H J Sutherland; E C Thiel
Journal:  Med Care       Date:  1993-11       Impact factor: 2.983

7.  EuroQol: health-related quality of life measurement. Results of the Swedish questionnaire exercise.

Authors:  R G Brooks; S Jendteg; B Lindgren; U Persson; S Björk
Journal:  Health Policy       Date:  1991-06       Impact factor: 2.980

8.  Measurement of quality of life in end-stage renal disease: the time trade-off approach.

Authors:  D N Churchill; G W Torrance; D W Taylor; C C Barnes; D Ludwin; A Shimizu; E K Smith
Journal:  Clin Invest Med       Date:  1987-01       Impact factor: 0.825

9.  Individual quality of life in patients undergoing hip replacement.

Authors:  C A O'Boyle; H McGee; A Hickey; K O'Malley; C R Joyce
Journal:  Lancet       Date:  1992-05-02       Impact factor: 79.321

10.  [Reliability and validity of the Visual Analogue Scale (VAS) (author's transl)].

Authors:  E Fähndrich; M Linden
Journal:  Pharmacopsychiatria       Date:  1982-05
View more
  65 in total

1.  Feasibility, validity and test-retest reliability of scaling methods for health states: the visual analogue scale and the time trade-off.

Authors:  X Badia; S Monserrat; M Roset; M Herdman
Journal:  Qual Life Res       Date:  1999-06       Impact factor: 4.147

2.  Culture, self-rated health and resource allocation decision-making.

Authors:  V L Wiseman
Journal:  Health Care Anal       Date:  1999

Review 3.  Valuing health-related quality of life. A review of health state valuation techniques.

Authors:  C Green; J Brazier; M Deverill
Journal:  Pharmacoeconomics       Date:  2000-02       Impact factor: 4.981

4.  The influence of ill-health experience on the valuation of health.

Authors:  X Badia; M Herdman; P Kind
Journal:  Pharmacoeconomics       Date:  1998-06       Impact factor: 4.981

5.  Understanding differences between self-ratings and population ratings for health in the EuroQOL.

Authors:  Ralph P Insinga; Dennis G Fryback
Journal:  Qual Life Res       Date:  2003-09       Impact factor: 4.147

6.  Validation of the KDQOL-SF: a dialysis-targeted health measure.

Authors:  J C Korevaar; M P Merkus; M A M Jansen; F W Dekker; E W Boeschoten; R T Krediet
Journal:  Qual Life Res       Date:  2002-08       Impact factor: 4.147

7.  Is a single-item visual analogue scale as valid, reliable and responsive as multi-item scales in measuring quality of life?

Authors:  A G E M de Boer; J J B van Lanschot; P F M Stalmeier; J W van Sandick; J B F Hulscher; J C J M de Haes; M A G Sprangers
Journal:  Qual Life Res       Date:  2004-03       Impact factor: 4.147

8.  The stability of utility scores: test-retest reliability and the interpretation of utility scores in elective total hip arthroplasty.

Authors:  D Feeny; C M Blanchard; J L Mahon; R Bourne; C Rorabeck; L Stitt; S Webster-Bogaert
Journal:  Qual Life Res       Date:  2004-02       Impact factor: 4.147

9.  Resident physician well-being and assessments of their knowledge and clinical performance.

Authors:  Thomas J Beckman; Darcy A Reed; Tait D Shanafelt; Colin P West
Journal:  J Gen Intern Med       Date:  2011-09-24       Impact factor: 5.128

Review 10.  A review and critique of studies reporting utility values for schizophrenia-related health states.

Authors:  Ifigeneia Mavranezouli
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.